Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29153
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tahir, Hasan | - |
dc.contributor.author | Mease, Philip J. | - |
dc.contributor.author | Kavanaugh, Arthur | - |
dc.contributor.author | Reimold, Andreas | - |
dc.contributor.author | Rech, Juergen | - |
dc.contributor.author | Hall, Stephen | - |
dc.contributor.author | GEUSENS, Piet | - |
dc.contributor.author | Pellet, Pascale | - |
dc.contributor.author | Delicha, Eumorphia Maria | - |
dc.contributor.author | Pricop, Luminita | - |
dc.contributor.author | Mpofu, Shephard | - |
dc.date.accessioned | 2019-09-12T09:48:24Z | - |
dc.date.available | 2019-09-12T09:48:24Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | RHEUMATOLOGY, 58(S3), p. 151-151 | - |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.uri | http://hdl.handle.net/1942/29153 | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: Final 5-year efficacy and safety results from the FUTURE 1 phase 3 trial | - |
dc.type | Journal Contribution | - |
local.bibliographicCitation.conferencedate | APR 30-MAY 02, 2019 | - |
local.bibliographicCitation.conferencename | Annual Conference of the British-Soceity-for-Rheumatology | - |
local.bibliographicCitation.conferenceplace | Birmingham, ENGLAND | - |
dc.identifier.epage | 151 | - |
dc.identifier.issue | S3 | - |
dc.identifier.spage | 151 | - |
dc.identifier.volume | 58 | - |
local.format.pages | 1 | - |
local.bibliographicCitation.jcat | M | - |
dc.description.notes | [Tahir, Hasan] Barts Hlth NHS Trust, Rheumatol, London, England. [Mease, Philip J.] Swedish Med Ctr, Dermatol, Seattle, WA USA. [Mease, Philip J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, Arthur] Univ Calif La Jolla, San Diego Sch Med, La Jolla, CA USA. [Reimold, Andreas] Dallas Vet Affairs Med Ctr, Dallas, TX USA. [Reimold, Andreas] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Rech, Juergen] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol, Erlangen, Germany. [Hall, Stephen] Emeritus Res, Rheumatol, Camberwell, Australia. [Geusens, Piet] Univ Hasselt, Rheumatol, Hasselt, Belgium. [Pellet, Pascale; Mpofu, Shephard] Novartis Pharma AG, Immunol & Dermatol, Basel, Switzerland. [Delicha, Eumorphia Maria] Novartis Pharma AG, Biostat, Basel, Switzerland. [Pricop, Luminita] Novartis Pharmaceut, Immunol Hepatol & Dermatol Franchise, E Hanover, NJ USA. | - |
local.publisher.place | OXFORD | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
dc.identifier.isi | 000478086100203 | - |
item.fullcitation | Tahir, Hasan; Mease, Philip J.; Kavanaugh, Arthur; Reimold, Andreas; Rech, Juergen; Hall, Stephen; GEUSENS, Piet; Pellet, Pascale; Delicha, Eumorphia Maria; Pricop, Luminita & Mpofu, Shephard (2019) Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: Final 5-year efficacy and safety results from the FUTURE 1 phase 3 trial. In: RHEUMATOLOGY, 58(S3), p. 151-151. | - |
item.fulltext | No Fulltext | - |
item.contributor | Tahir, Hasan | - |
item.contributor | Mease, Philip J. | - |
item.contributor | Kavanaugh, Arthur | - |
item.contributor | Reimold, Andreas | - |
item.contributor | Rech, Juergen | - |
item.contributor | Hall, Stephen | - |
item.contributor | GEUSENS, Piet | - |
item.contributor | Pellet, Pascale | - |
item.contributor | Delicha, Eumorphia Maria | - |
item.contributor | Pricop, Luminita | - |
item.contributor | Mpofu, Shephard | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 1462-0324 | - |
crisitem.journal.eissn | 1462-0332 | - |
Appears in Collections: | Research publications |
WEB OF SCIENCETM
Citations
1
checked on Aug 5, 2024
Page view(s)
72
checked on Jul 28, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.